Drug Description in Trials / DrugBank / KEGG DRUG
Search results
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 |
|---|---|---|---|---|---|---|
| 1 | ANTI-VON willebrand factor nanobody, caplacizumab (D11160) | - | - | - | - | 1件: 64 64 💬
|
| 2 | ANTI-VON willebrand factor nanobody, INN = caplacizumab (D11160) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
(D11160) 💬
| 1件: VWF VWF 💬
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬
|
| 3 | Caplacizumab (D11160) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
(D11160) 💬
| 1件: VWF VWF 💬
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 2件: 63 63, 64 💬
|